Back to today’s briefing

Story perspectives

FDA Regulator Resigns Amid Elevidys Controversy and Criticism

7/30/2025

50 9

Summary

Story summary

Vinay Prasad, a prominent FDA regulator, stepped down amid growing controversy surrounding his management of Sarepta Therapeutics' gene therapy, Elevidys, which is connected to three fatalities. His resignation seeks to protect the FDA's integrity as criticism mounts over his decisions on Covid vaccines and Elevidys, exposing deep divisions over drug safety and accessibility.

1 of 1

Story summary

Vinay Prasad, a prominent FDA regulator, stepped down amid growing controversy surrounding his management of Sarepta Therapeutics' gene therapy, Elevidys, which is connected to three fatalities. His resignation seeks to protect the FDA's integrity as criticism mounts over his decisions on Covid vaccines and Elevidys, exposing deep divisions over drug safety and accessibility.